Bristol Myers Squibb, US0897961004

Bristol Myers Squibb stock heads into the open after a 1.3 percent drop

Published on 09/18/2026 at 07:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 17, 2026, Bristol Myers Squibb stock finished at USD 62.77 on the New York Stock Exchange, down 1.3 percent on the day while the broader US market moved higher. Today, investors watch recent immunology data presentations for potential sentiment impact.

Impressionistische Aquarellmalerei der New Yorker Skyline bei Dämmerung, Wolkenkratzer-Silhouetten in weichen Blau- und Bernsteinwaschen mit Lichtreflexionen auf nassen Straßen
Bristol-Myers Squibb US0897961004 Aquarell New Yorker Skyline beleuchtet durch Abenddämmerung mit goldenen Straßenreflexionen, Illustration mit AI erstellt.

Bristol Myers Squibb stock closed at USD 62.77 on the New York Stock Exchange on September 17, 2026, down 1.3 percent from the prior session in regular trading. The shares underperformed major US equity benchmarks, which advanced on the same day.

September 17, 2026 in numbers

Bristol Myers Squibb Inc. (ISIN US0897961004, NYSE: BMY) ended the September 17, 2026 session at USD 62.77 after slipping 0.83 USD, or 1.31 percent, from its previous close in regular hours trading, according to MarketBeat data summarizing the New York Stock Exchange session for that date.MarketBeat Nasdaq quote information indicated a regular-session close of USD 62.84 with a 1.19 percent loss, with after-hours trading nudging the price slightly higher, confirming that the main US venue close remained in the low USD 62 range on September 17, 2026.CNBC The drop left the stock trading modestly above the GF Value estimate of USD 56.60 cited by GuruFocus, which characterized BMY shares as about 12.4 percent overvalued at a price point of USD 63.60, framing the latest pullback against valuation concerns.GuruFocus With Wall Street indices rising on September 17, 2026, as US stocks broadly gained, Bristol Myers Squibb lagged the upbeat market tone.Sohu

Today’s focus on recent data

On September 17, 2026, Bristol Myers Squibb highlighted new long term immunology data, presenting two year results for its Sotyktu (deucravacitinib) therapy in adults with psoriatic arthritis, emphasizing durable efficacy and a consistent safety profile in a corporate press release.Bristol Myers Squibb These clinical results and their implications for the company’s immunology portfolio remain a key narrative for investors heading into today’s US session. Broader US market conditions, including the recent advance in major indices and ongoing moves in sectors linked to healthcare and pharmaceuticals, may also shape sentiment around the stock as trading resumes today.

Disclaimer...

en | US0897961004 | BRISTOL MYERS SQUIBB | boerse | 70122397 | bgmi